Hongliang Xin

MeSH headings : Animals; Antineoplastic Agents / administration & dosage; Antineoplastic Agents / pharmacokinetics; Biomimetic Materials / chemistry; Blood Vessels / drug effects; Blood Vessels / metabolism; Cell Line, Tumor; Cell Survival / drug effects; Cells, Cultured; Dextrans / chemistry; Drug Delivery Systems; Human Umbilical Vein Endothelial Cells / drug effects; Human Umbilical Vein Endothelial Cells / metabolism; Humans; Mice, Nude; Microtubules / enzymology; Microtubules / metabolism; Nanostructures / chemistry; Neoplasm Transplantation; Neoplasms / blood supply; Neoplasms / drug therapy; Neoplasms / metabolism; Oligopeptides / chemistry; Paclitaxel / administration & dosage; Paclitaxel / pharmacokinetics; Tumor Necrosis Factor-alpha / chemistry; Tumor Necrosis Factor-alpha / pharmacokinetics

TL;DR: A "relay drug delivery" system based on two distinct modules that can specifically induce tumor blood vessel inflammation generation and an execution biomimetic nanocarrier B that can accumulate at the tumor site by receiving the broadcasting signals generated by NCA is developed for amplifying active tumor targeting signal and enhancing antitumor therapy. (via Semantic Scholar)

MeSH headings : Animals; Biomimetic Materials / chemistry; Biomimetic Materials / pharmacokinetics; Biomimetics; Blood Platelets / cytology; Bone and Bones / metabolism; Cell Line, Tumor; Cell Membrane / metabolism; Cellular Microenvironment; Disease Models, Animal; Drug Carriers / chemistry; Drug Carriers / pharmacokinetics; Humans; Mice; Multiple Myeloma / complications; Multiple Myeloma / drug therapy; Multiple Myeloma / metabolism; Multiple Myeloma / pathology; Nanoparticles / chemistry; Thrombosis / complications; Thrombosis / drug therapy

TL;DR: A platelet-membrane-coated biomimetic nanocarrier, which can sequentially target the bone microenvironment and Myeloma cells to enhance the drug availability at the myeloma site and decrease off-target effects, is developed for inhibiting multiple myelomas growth and simultaneously eradicating thrombus complication. (via Semantic Scholar)

author keywords: drug delivery; immunotherapy; anti-PD1; IDO; microneedle

MeSH headings : Animals; Cell Cycle Checkpoints / drug effects; Drug Delivery Systems; Immunosuppression Therapy; Immunotherapy / methods; Indoleamine-Pyrrole 2,3,-Dioxygenase / therapeutic use; Melanoma / therapy; Programmed Cell Death 1 Receptor / therapeutic use; Skin Neoplasms / therapy; Tumor Microenvironment

TL;DR: This synergistic immunotherapy strategy locally targets the immunoinhibitory receptor programmed cell death protein 1 (PD1) and immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) for the treatment of melanoma through a microneedle-based transcutaneous delivery approach and achieves potent antitumor efficacy. (via Semantic Scholar)